# Supporting Information 

for

# Adaptable 2,5-bis((1,2,3-triazol-4-yl)methoxy)pyrazine ligands for the simple self-assembly of homoleptic 1D coordination polymers 

Marryllyn E. Donaldon, ${ }^{\text {a }}$ Tyson N. Dais, ${ }^{\text {a }}$ Gareth J. Rowlands, ${ }^{\text {ab }}$ Brodie E. Matheson, ${ }^{\text {a }}$ and Paul G. Plieger* ${ }^{*}$

${ }^{a}$ School of Natural Sciences (SNS), Massey University, Tennent Drive, Palmerston North, 4410, New Zealand

## E-mail: p.g.plieger@massey.ac.nz

## Table of Contents

S1: Materials and Methods ..... 2
S1.1 Synthesis and characterisation of the azido derivatives. ..... 3
S1.3 Synthesis and characterisation of the TzOP ligands ..... 9
S1.4 SCXRD of organic compounds ..... 12
S2 Characterization of Products ..... 13
S2.1 UV-Vis Specroscopy ..... 13
S2.2 L1 and L2 complexes ..... 14
S2.3 L3complexes ..... 19
S2.4 L3complexes ..... 20
S3 NMR Spectra ..... 23
S4 Infrared Spectra ..... 31
References ..... 40

## Experimental section

## S1: Materials and Methods

## Materials

All reactions were performed under aerobic conditions using chemicals and solvents as purchased from commercial sources, unless stated otherwise. MeOH was dried over activated $3 \AA$ molecular sieves. CAUTION: Organic azides are potentially explosive and should be handled with care.

## Instrumentation

- ${ }^{1} \mathrm{H}$ NMR and ${ }^{13} \mathrm{C}$ NMR spectra were recorded using a Bruker Avance 500 MHz spectrometer. Shifts are reported relative to residual solvent.
- IR spectra were recorded on solid-state samples using a ThermoFischer Nicolet iS5 equipped with an iD7 diamond ATR sampling accessory.
- HRMS was recorded using a ThermoScientific Q Exactive Focus Hybrid Quadrupole-Orbitrap mass spectrometer.
- UV-Vis spectra were recorded using a Shimadzu UV-3101PC spectrophotometer.
- Single-crystal X-ray diffraction experiments were carried out on a Bruker D8 Venture diffractometer equipped with an $\mathrm{I} \mu \mathrm{S}$ Diamond microfocus $\mathrm{Cu}-\mathrm{K} \alpha$ source $(\lambda=1.54178 \AA$ ) and a Photon III detector. Single crystals were mounted on MiTeGen mylar loops using Fomblin Y® and cooled to 100 K with an Oxford Cryostream 800. CCDC deposition numbers: 2301236-2301247


## S1.1 Synthesis and characterisation of the azido derivatives

## a1: Allyl azide ${ }^{1}$

3-Bromo-1-propene ( $0.790 \mathrm{~mL}, 8.89 \mathrm{mmol}$, 1 equiv.) was added to a stirred suspension of sodium azide $(0.7437 \mathrm{~g}$, $11.44 \mathrm{mmol}, 1.29$ equiv.) in DMF ( 6 mL ). After stirring at
 RT for 1 day, 10 ml of $\mathrm{H}_{2} \mathrm{O}$ was added to the solution, and the product was extracted with $\mathrm{CH}_{2} \mathrm{Cl}_{2}$ (15 $\mathrm{mL} x 3$ ). The combined organic phases were concentrated to approximately half the original volume under reduced pressure (maintaining a temperature below $10^{\circ} \mathrm{C}$ ). The crude product was obtained within solution a in $42 \%$ yield (calculated from ${ }^{1} \mathrm{H}$ NMR) and was used without further purification.
${ }^{1} \mathbf{H}$ NMR ( $400 \mathrm{MHz}, \mathrm{CDCl}_{3}$ ): $\delta 5.80-5.87$ (ddt, $1 \mathrm{H}, J-1=16.44 ; J-2=10.30 ; J-3=6.24 \mathrm{~Hz}$ ), $5.27(\mathrm{~m}$, $2 \mathrm{H}), 3.75(\mathrm{~d}, 2 \mathrm{H}, J=5.39 \mathrm{~Hz}) \mathrm{ppm}$.

## a2: Azidobutane ${ }^{2}$

DMSO ( 6 mL ) was added to a stirred solution of sodium azide ( $0.7116 \mathrm{~g}, 10.95 \mathrm{mmol}, 1.5$ equiv.) in water ( 2 mL ) at RT. 1-Bromopropane $(0.789 \mathrm{~mL}, 7.30$
 mmol, 1 equiv.) was then added. The mixture was stirred at $50^{\circ} \mathrm{C}$ for 4 hours, after which two layers formed. The top layer contained the crude product as a clear oil, and was decanted for use in subsequent click reactions. The crude product was obtained in $97 \%$ yield $(0.44 \mathrm{~g})$. Analytical data is consistent with the literature.
${ }^{1} \mathbf{H}$ NMR ( $400 \mathrm{MHz}, \mathrm{CDCl}_{3}$ ): $\delta 3.26(\mathrm{t}, 2 \mathrm{H}, \mathrm{J}=6.95 \mathrm{~Hz}$ ), 1.56-1.62 (pent, $2 \mathrm{H}, J=14.69 ; 7.24 ; 7.24$ $\mathrm{Hz}), 1.37-1.47(\mathrm{sext}, 2 \mathrm{H}, J-1=22.40 ; J-2=7.39 ; J-3=7.39 \mathrm{~Hz}), 0.92-0.96(\mathrm{t}, 3 \mathrm{H}, J=7.37 \mathrm{~Hz}) \mathrm{ppm}$. Mass (m/z): 122.05 (100), $123.05(5)[\mathrm{M}+\mathrm{Na}]$

## a3: Phenyl azide ${ }^{3}$

A solution of $\mathrm{NaNO}_{2}(0.2908 \mathrm{~g}, 4.2 \mathrm{mmol}, 1.11$ equiv.) in water ( 6 mL ) was added dropwise to a stirred solution of aniline ( $0.35 \mathrm{~g}, 3.8 \mathrm{mmol}, 1$ equiv.) in $\mathrm{HCl}(2 \mathrm{M}, 11 \mathrm{~mL})$ cooled in an ice bath. The reaction mixture was allowed to
 stir for one hour, after which sodium azide ( $0.6850 \mathrm{~g}, 10 \mathrm{mmol}, 2.8$ equiv.) dissolved in 12 mL water was added dropwise. The reaction was stirred for a further 4 hours at RT. The mixture was extracted with ethyl acetate ( $30 \mathrm{~mL} x 3$ ) and the combined organic extracts were washed with $\mathrm{H}_{2} \mathrm{O}$, dried over anhydrous $\mathrm{Na}_{2} \mathrm{SO}_{4}$, filtered, and concentrated under reduced pressure to give $\mathbf{a 3}$ as a transparent yellow oil ( $0.3559 \mathrm{~g}, 88.49 \%$ ). The crude product was used directly without purification.
${ }^{1} \mathbf{H} \mathbf{N M R}\left(\mathrm{CDCl}_{3}, 500 \mathrm{MHz}\right): \delta 7.33-7.37(\mathrm{t}, 2 \mathrm{H}, J=7.89 \mathrm{~Hz}), 7.12-7.15(\mathrm{t}, 1 \mathrm{H}, J=7.42 \mathrm{~Hz}), 7.02-7.04$ $(\mathrm{d}, 2 \mathrm{H}, J=7.64 \mathrm{~Hz}) \mathrm{ppm}$. The analytical data are consistent with the literature. ${ }^{4}$

## a4: Benzyl Azide ${ }^{5}$

Benzyl bromide ( $0.350 \mathrm{~mL}, 2.9 \mathrm{mmol}, 1$ equiv.) was added dropwise to a stirred solution of sodium azide ( $0.285 \mathrm{~g}, 4.4 \mathrm{mmol}, 1.5$ equiv.) in (3:1 acetone/water, 4
 mL ) at RT and allowed to react for 3 hours. The reaction was diluted with water and extracted with ethyl acetate ( $10 \mathrm{~mL} x 3$ ). The combined organic layers were washed with brine, dried over anhydrous $\mathrm{MgSO}_{4}$, filtered, and concentrated under reduced pressure at $25^{\circ} \mathrm{C}$, to give crude benzyl azide as a transparent light-yellow oil in $95 \%$ yield $(0.370 \mathrm{~g})$. The product was used without further purification.
${ }^{1} \mathbf{H}$ NMR $\left(\mathrm{CDCl}_{3}, 500 \mathrm{MHz}\right): \delta=7.31-7.41(\mathrm{~m}, 5 \mathrm{H}), 4.34(\mathrm{~s}, 2 \mathrm{H}) \mathrm{ppm}$. The analytical data are consistent with the literature. ${ }^{6}$

## S1.2 Synthesis and characterisation of the alkyne derivative

## 1: 2,5-Dimethylpyrazine-1,4-N-oxide ${ }^{7}$

A solution of $m$-CPBA $77 \%(39.955 \mathrm{~g}, 178.28 \mathrm{mmol}, 3$ equiv.) in EtOAc ( 66 mL ) was washed with brine ( 66 mL ). The organic layer was separated, dried with $\mathrm{MgSO}_{4}$,
 and filtered. 2,5-Dimethylpyrazine ( $6.5 \mathrm{~mL}, 59.428 \mathrm{mmol}, 1$ equiv.) was slowly added to the filtrate and the mixture was stirred for 24 hours at RT. The resulting white precipitate was collected over a glass frit, and washed with EtOAc ( 3 x 15 mL ), to remove any byproducts. The white solid, was dried to give 1 in an $87 \%$ yield $(7.2660 \mathrm{~g})$.
${ }^{1}{ }^{1}$ NMR ( 500 MHz, DMSO- $\mathrm{d}_{6}$ ): $\delta 8.48(\mathrm{~s}, 1 \mathrm{H}), 2.23(\mathrm{~s}, 3 \mathrm{H}) \mathrm{ppm}$.

## 2: 2,5-Bis(acetoxymethyl)pyrazine ${ }^{7}$

Method 1: A stirred suspension of $1(5.001 \mathrm{~g}$, 35.7 mmol , 1 equiv.) in acetic anhydride ( 25 mL , $260 \mathrm{mmol}, 7.4$ equiv.) was heated at $158^{\circ} \mathrm{C}$ for 7 hours, then allowed to cool to RT and stirred for a further 16 hours. The acetic anhydride was
 removed under reduced pressure to give a viscous black/brown liquid. Diethyl ether ( 125 mL ) was added to the crude product, as an extraction solvent, and stirred vigorously for 2 hours, then stood for 3 hours at RT. The solution was then filtered through a thin pad of Celite, and the yellow filtrate collected. The solid crude residue was washed with additional 10 mL x 4 until minimal colour was extracted with $\mathrm{Et}_{2} \mathrm{O}$. The combined filtrates were concentrated under reduced pressure. The product was washed with RT 3:7 EtOAc:Hexane, and the remaining dark orange product was hot recrystallised from 3:7 EtOAc:Hexane, affording 2 as a light yellow crystalline in $25 \%$ yield.

## Optimisation of Method 2:

The low yield of this reaction was a bottleneck for ligand synthesis. To increase the reaction efficiency in both time and yield, an initial reaction of compound 1 with 7 equiv. of acetic anhydride at $100^{\circ} \mathrm{C}$ for 1 hour indicated partial conversion to the desired product. A series of reactions lead to optimised conditions of compound 1 with 5 equiv. of acetic anhydride at $140^{\circ} \mathrm{C}$ for 3 hours.

## Method 2:

Acetic anhydride ( $1.87 \mathrm{~mL}, 19.5 \mathrm{mmol}, 5$ equiv.) was bubbled with Ar for one minute and added to a microwave vial containing 2,5-dimethylpyrazine (1) ( $0.55 \mathrm{~g}, 3.9 \mathrm{mmol}, 1$ equiv.) which was sealed, then heated under stirring to $140^{\circ} \mathrm{C}$ for 3 hours using a microwave The excess acetic anhydride was removed under reduced pressure. Diethyl ether $(40 \mathrm{~mL})$ was added to the black solid and stirred at RT for two hours. A black solid byproduct was removed by filtration, and the yellow filtrate was concentrated under reduced pressure. The resulting yellow solid was purified by hot recrystallisation with EtOAc:Hexane ( $1: 3$ ) ( $0.37 \mathrm{~g}, 47 \%$ ) affording 2 as yellow plate crystals in a $47 \%$ yield $(0.37 \mathrm{~g})$.
${ }^{1} \mathbf{H}$ NMR ( $500 \mathrm{MHz}, \mathrm{CDCl}_{3}$ ): $\delta 8.61,(\mathrm{~s}, 2 \mathrm{H}), 5.25(\mathrm{~s}, 2 \mathrm{H}), 2.15(\mathrm{~s}, 3 \mathrm{H}) \mathrm{ppm}$. Mass $(\mathrm{m} / \mathrm{z}):[\mathrm{M}+\mathrm{H}]: 225.13$ (100), $226.10(9)[\mathrm{M}+\mathrm{Na}]: 247.16(100), 248.16(11)$. These results agreed with literature values.


Figure S1 Product 2 yield: held at increasing temperature (a 1:14 1: $\mathrm{Ac}_{2} \mathrm{O}$ ratio, held for one hour) yield increase


Figure S2 Product 2 yield: with variable $\mathrm{Ac}_{2} \mathrm{O}$ to reagent 1 ratio (held at $130{ }^{\circ} \mathrm{C}$ for three hours). The optimal ratio was 5:1.


Figure S 3 Product 2 yield: held at temperature for three hours (in a 5:1 ratio of $\mathrm{Ac}_{2} \mathrm{O}: \mathbf{1}$ ).

## X-ray crystal structure of 2: 2,5-bis(acetoxymethyl)pyrazine

Yellow plate crystals suitable for single-crystal X-ray diffraction analysis were obtained from the addition of water into a methanolic solution of $\mathbf{2}$. The data was solved and refined in the monoclinic space group $P 2_{1} / c$, with the twin law $[-1,0,0,0,-1,0,0,0,1]$ and BASF $[0.450(6)]$. The asymmetric unit contains half unit of the molecule with no additional solvent present.

Crystal Data for $\mathrm{C}_{10} \mathrm{H}_{12} \mathrm{~N}_{2} \mathrm{O}_{4}(M=224.22 \mathrm{~g} / \mathrm{mol})$ : monoclinic, space group $P 2_{1} / c$ (no. 14), $a=$ $11.3960(17) \AA, b=5.4689(8) \AA, c=8.3487(13) \AA, \beta=90.197(9)^{\circ}, V=520.32(14) \AA^{3}, Z=$ $2, T=100 \mathrm{~K}, \mu(\mathrm{CuK} \alpha)=0.949 \mathrm{~mm}^{-1}, \rho_{\text {calc }}=1.431 \mathrm{~g} \mathrm{~cm}^{-3}, 5326$ reflections measured $\left(7.758^{\circ} \leq 2 \Theta \leq 136.37^{\circ}\right), 927$ unique $\left(R_{\text {int }}=0.0966, \mathrm{R}_{\text {sigma }}=0.0662\right)$ which were used in all calculations. The final $R_{1}$ was $0.0780(I \geq 2 \sigma(I))$ and $w R_{2}$ was 0.2152 (all data).


Figure S4 X-ray crystal structure showing a whole molecule of compound 2, with labelled heteroatoms. Ellipsoids are drawn at the $50 \%$ probability level.

## 3: 2,5-Bis(hydroxymethyl)pyrazine ${ }^{7}$



Fresh NaOMe solution was prepared by the piecewise addition of solid $\mathrm{Na}(0.3236 \mathrm{~g}, 14.1 \mathrm{mmol} 2$ equiv.) into dry $\mathrm{MeOH}\left(3 \mathrm{~mL}\right.$ ), followed by stirring for 15 minutes until no more solid remained. ${ }^{8}$

To the freshly prepared NaOMe was added a solution of $\mathbf{2}(1.5781 \mathrm{~g}, 7.04 \mathrm{mmol}, 1$ equiv.) in dry MeOH $(35 \mathrm{~mL})$ under argon, which was stirred for 3 hours at RT. The reaction was quenched by adding solid $\mathrm{NH}_{4} \mathrm{Cl}(0.05 \mathrm{~g})$. The solvent was concentrated under reduced pressure, resulting in the 2,5bis(hydroxymethyl)pyrazine product as a beige-white solid, 0.9152 g , in a $92.8 \%$. This procedure resulted in the product $\mathbf{3}$, that required no further purification, its characterisation agreeing with literature values. ${ }^{7}$
${ }^{1}{ }^{1}$ NMR ( $500 \mathrm{MHz}, \mathrm{CDCl}_{3}$ ): $\delta 8.57$, (s $1 \mathrm{H}, \mathrm{Ar}-\mathrm{H}$ ), 4.84, (s, 2H, CH2 $), 2.98$ (br, $1 \mathrm{H},-\mathrm{OH}$ ) ppm. MS $(\mathrm{m} / \mathrm{z}):[\mathrm{M}+\mathrm{H}] 141.17$ (100), 142.11 (7) These results agreed with literature values. ${ }^{7}$


## 4: 2,5-Bis((prop-2-yn-1-yloxy)methyl)pyrazine

Adapted from Delso, et al. ${ }^{9}$ Compound $\mathbf{3}(0.743 \mathrm{~g}, 5.3 \mathrm{mmol}, 1$ equiv.) was ground with a mortar and pestle into a fine beige powder, that was suspended in 65 mL of DMF, bubbled with Ar, and cooled to $0^{\circ} \mathrm{C}$. To this stirred solution, $\mathrm{NaH}(0.848 \mathrm{~g}, 21.2 \mathrm{mmol}, 4$ equiv. $)$ was added in small portions. When hydrogen liberation stopped, propargyl bromide ( $0.95 \mathrm{~mL}, 10.75 \mathrm{mmol}, 3$ equiv.) was added dropwise. The reaction solution was stirred overnight at RT. The mixture was poured into 100 mL of ice water and the product extracted with hexane ( $3 \times 100 \mathrm{~mL}$ ). The combined organic layers were dried with $\mathrm{MgSO}_{4}$, filtered and the solvent was removed under vacuum. Compound $\mathbf{4}$ was obtained as a clear, pale-yellow oil ( $0.713 \mathrm{~g}, 83 \%$ ).
${ }^{1}$ H NMR ( 500 MHz, DMSO- $\mathrm{d}_{6}$ ): $\delta 8.63(\mathrm{~s}, 2 \mathrm{H}), 4.68(\mathrm{~s}, 4 \mathrm{H}), 4.30(\mathrm{~d}, 4 \mathrm{H}, \mathrm{J}=2.44 \mathrm{~Hz}), 3.51(\mathrm{t}, 2 \mathrm{H}, \mathrm{J}$ $=2.4 \mathrm{~Hz}$ ) ppm. ${ }^{13} \mathbf{C}$ NMR ( 126 MHz ; DMSO-d $\mathrm{d}_{6}$ ): $\delta 152.21,142.97,80.31,78.29,70.29,58.16 \mathrm{ppm}$. IR: $\bar{v}_{\text {max }}$ 2954, 2923, 2853, 1666, 1456, 1377, 1260, $736 \mathrm{~cm}^{-1}$. HRMS (m/z) (ESI+): calculated for $\mathrm{C}_{12} \mathrm{H}_{13} \mathrm{~N}_{2} \mathrm{O}_{2}{ }^{+} m / z=217.0972[\mathrm{~L}+\mathrm{H}]^{+}$. Found $(m / z): 217.0968[\mathrm{~L}+\mathrm{H}]^{+}, 239.0787[\mathrm{~L}+\mathrm{Na}]$.

## S1.3 Synthesis and characterisation of the TzOP ligands

## General CuAAC click synthesis of L1-L4:

The pyrazine bis-alkyne compound, $\mathbf{4}$, ( 1 equiv.) was reacted with the appropriate azide ( 2 equiv.) in a DCM: $\mathrm{H}_{2} \mathrm{O}$ (10:1) solution. A catalytic amount ( 0.1 equiv.) of sodium ascorbate was added and stirred at RT for 5 min until dissolved. An aqueous solution of $\mathrm{Cu}(\mathrm{OAc})_{2} \cdot 6 \mathrm{H}_{2} \mathrm{O}(0.1$ equiv. 0.5 M ) was added to the reaction. After stirring overnight, the reaction was washed with $\mathrm{H}_{2} \mathrm{O}$ until no further colour was removed. The organic solutions were also washed with $5 \mathrm{wt} \%$ EDTA aqueous solution followed by passage of the organic fraction through a silica plug and then concentrated under reduced pressure. The crude product was then dissolved in a minimal amount of MeOH , and the product crystallised upon the addition of water.

Ligand L1: 2,5-bis(((1-allyl-1H-1,2,3-triazol-4-yl)methoxy)methyl)pyrazine
Following the general CuAAC method, using azido propene (a1) a light brown precipitate of $\mathbf{L} 1$ was obtained in an $81 \%$ yield.

m.p. $90-97{ }^{\circ} \mathrm{C} .{ }^{1} \mathbf{H}$ NMR ( 500 MHz, DMSO- $\mathrm{d}_{6}$ ) $\delta:=8.63(\mathrm{~s}, 2 \mathrm{H}), 8.14(\mathrm{~s}, 2 \mathrm{H}), 6.04(\mathrm{ddt}, 2 \mathrm{H}, \mathrm{J}-1=$ $6.29, J-2=10.38, J-3=5.26 \mathrm{~Hz}), 5.25(\mathrm{~d}, 2 \mathrm{H}, J=10.2 \mathrm{~Hz}), 5.15(\mathrm{~d}, 2 \mathrm{H}, J=16.94 \mathrm{~Hz}) 5.01(\mathrm{~d}, 4 \mathrm{H}, J=$ 5.93 Hz ), 4.68 ( $\mathrm{s}, 8 \mathrm{H}$ ) ppm. ${ }^{13} \mathbf{C}$ NMR ( 126 MHz , DMSO- $\mathrm{d}_{6}$ ) $\delta:=152.5,144.1,142.8,133.2,124.7$, $119.2,70.8,64.0,52.1,36.2,31.2 \mathrm{ppm}$. IR: $\bar{v}_{\text {max }} 3430,3143,2929,1664,1490,1464,1420,1390,1338$, 1260, 1223, 1140, 1095, 1049, 1033, 993, 942, 886, 834, $793 \mathrm{~cm}^{-1}$. HRMS ( $\mathbf{m} / \mathrm{z}$ ) (ESI+): calculated for $\mathrm{C}_{18} \mathrm{H}_{23} \mathrm{~N}_{8} \mathrm{O}_{2}{ }^{+} \mathrm{m} / \mathrm{z}=383.1085[\mathrm{M}+\mathrm{H}]^{+}$. Found $m / z=383.05[\mathrm{M}+\mathrm{H}] ; 405.12[\mathrm{M}+\mathrm{Na}] ; 787.28[2 \mathrm{M}+\mathrm{Na}]$.

## L2: 2,5-Bis(((1-butyl-1H-1,2,3-triazol-4-yl)methoxy)methyl)pyrazine

Following the general CuAAC method, using azido butane (a2) a white precipitate of $\mathbf{L} \mathbf{2}$ was obtained in a $78 \%$ yield.

m.p. $89-96{ }^{\circ} \mathrm{C} .{ }^{1} \mathrm{H}$ NMR ( 500 MHz, DMSO- $\mathrm{d}_{6}$ ): $\delta 8.63(2 \mathrm{H}, \mathrm{s}), 8.17(2 \mathrm{H}, \mathrm{s}), 4.67(4 \mathrm{H}, \mathrm{s}), 4.66(4 \mathrm{H}$, s), $4.34(4 \mathrm{H}, \mathrm{t}, J=7.05 \mathrm{~Hz}), 1.78(4 \mathrm{H}, \mathrm{q}, J=7.33 \mathrm{~Hz}), 1.23(4 \mathrm{H}$, hex, $J=7.45), 0.88(6 \mathrm{H}, \mathrm{t}, J$ $=7.38 \mathrm{~Hz}) \mathrm{ppm} .{ }^{13} \mathbf{C}$ NMR ( 126 MHz ; DMSO- $\mathrm{d}_{6}$ ): $\delta 152.5,143.9,142.8,124.5,70.7,64.1,49.5$, $32.1,19.5,13.8 \mathrm{ppm}$ IR: $\bar{v}_{\max } 3430,3118,2955,2931,2872,1669,1484,1458,1375,1349$, 1255, 1218, 1143, 1091, 1056, 1035, 1027, 991, 941, 870, 802, $776 \mathrm{~cm}^{-1}$. HRMS ( $\boldsymbol{m} / \boldsymbol{z}$ ) (ESI+): calculated for $\mathrm{C}_{20} \mathrm{H}_{31} \mathrm{~N}_{8} \mathrm{O}_{2}{ }^{+} \mathrm{m} / \mathrm{z}=415.2560[\mathrm{M}+\mathrm{H}]^{+}$. Found $m / z=415.2564[\mathrm{M}+\mathrm{H}]+, 437.2380$ [L+Na]+

## L3: 2,5-Bis(((1-phenyl-1H-1,2,3-triazol-4-yl)methoxy)methyl)pyrazine

Following the general CuAAC method, using phenyl azide (a3), a pale orangebrown precipitate of $\mathbf{L} \mathbf{3}$ was obtained in a $74 \%$ yield.

m.p. $177-184{ }^{\circ} \mathrm{C} .{ }^{\mathbf{1}} \mathbf{H}$ NMR ( $500 \mathrm{MHz}, ~ D M S O-d_{6}$ ): $\delta 8.89(\mathrm{~s}, 2 \mathrm{H}), 8.71(\mathrm{~s}, 2 \mathrm{H}), 7.91(\mathrm{~d}, 4 \mathrm{H}, J=8.31$ $\mathrm{Hz}), 7.60(\mathrm{t}, 4 \mathrm{H}, J=7.62 \mathrm{~Hz}), 7.50(\mathrm{t}, 2 \mathrm{H}, J=7.35 \mathrm{~Hz}), 4.78(\mathrm{~s}, 4 \mathrm{H}), 4.76(\mathrm{~s}, 4 \mathrm{H}) \mathrm{ppm} .{ }^{13} \mathbf{C}$ NMR (126 MHz ; DMSO-d $\mathrm{d}_{6}$ : $\delta 152.5,145.2,142.9,137.1,130.4,129.1,122.9,120.5,70.9,63.9 \mathrm{ppm}$. IR: $\bar{\nu}_{\max } 3400,3125,3078,2920,2860,1598,1557,1501,1480,1466,1445,1386,1345,1264,1236,1196$, 1095, 1053,1030, 998, 944, 758, $689 \mathrm{~cm}^{-1}$. HRMS (m/z) (ESI+): calculated for $\mathrm{C}_{24} \mathrm{H}_{24} \mathrm{~N}_{8} \mathrm{O}_{2}{ }^{+} \mathrm{m} / \mathrm{z}=$ $455.1938[\mathrm{~L}+\mathrm{H}]^{+}$. Found (m/z): $455.1933[\mathrm{~L}+\mathrm{H}], 477.1752[\mathrm{~L}+\mathrm{Na}]$.

## L4: 2,5-bis(((1-benzyl-1H-1,2,3-triazol-4-yl)methoxy)methyl)pyrazine

Following the general CuAAC method, using benzyl azide (a4), a pale brown precipitate of $\mathbf{L 4}$ obtained in a $63 \%$ yield.

m.p. $125-129{ }^{\circ} \mathrm{C} .{ }^{\mathbf{1}} \mathbf{H}$ NMR ( 500 MHz ,

DMSO-d ${ }_{6}$ : $\delta 8.62(\mathrm{~s}, 2 \mathrm{H}), 8.24(\mathrm{~s}, 2 \mathrm{H}), 7.35-7.37(\mathrm{~m}, 4 \mathrm{H}), 7.29-7.32(\mathrm{~m}, 6 \mathrm{H}), 5.59(\mathrm{~s}, 2 \mathrm{H}), 4.67$ ( $\mathrm{s}, 4 \mathrm{H}$ ), $4.66(\mathrm{~s}, 4 \mathrm{H}) \mathrm{ppm} .{ }^{13} \mathbf{C}$ NMR ( 126 MHz ; DMSO-d $\mathrm{d}_{6}$ ): $\delta 152.5144 .4,142.8,136.5,129.2$, 128.6, 128.4, 124.8, 70.8, 64.0, 53.2 ppm. IR: $\bar{v}_{\max } 3408,3130,3065,3031,2925,2096,1605$, $1497,1455,1435,1362,1333,1217,1157,1123,1076,1053,1030,987,824,720,696,576 \mathrm{~cm}^{-}$
${ }^{1}$. HRMS (m/z) (ESI+): calculated for $\mathrm{C}_{26} \mathrm{H}_{27} \mathrm{~N}_{8} \mathrm{O}_{2}{ }^{+} \mathrm{m} / \mathrm{z}=483.2251[\mathrm{~L}+\mathrm{H}]^{+}$. Found $(\mathrm{m} / \mathrm{z})$ : $505.2065[\mathrm{~L}+\mathrm{Na}], 483.2247[\mathrm{~L}+\mathrm{H}]$.

## X-ray crystal structure of L2: 2,5-bis(((1-butyl-1H-1,2,3-triazol-4-yl)methoxy)methyl)pyrazine

White needle-like crystals suitable for single-crystal X-ray diffraction analysis were obtained from the addition of water into a methanolic solution of $\mathbf{L} 2$. The data was solved and refined in the triclinic space group $P \overline{1}$ with the asymmetric unit containing two separate $\mathbf{L} \mathbf{2}$ fragments. Crystallographic symmetry generates rows of ligands of alternating orientations about the central pyrazine (Fig. S5). The two fragments in the asymmetric unit adopt different Z-shaped conformations, with the 'bend' of the ligand occurring in different sides of the ether oxygen atom. The O1 oxygen lies relatively planar to the N1 pyrazine with a C1-C2-C3-O1 dihedral of $27.5(3)^{\circ}$, and relatively perpendicular to the N 2 triazole with an O1-C4-C5-C6 dihedral of $76.2(3)^{\circ}$, compared to the second ligand orientation where the O 2 ether oxygen lies more perpendicular to its N 5 pyrazine with a $\mathrm{C} 11-\mathrm{C} 12-\mathrm{C} 13-\mathrm{O} 2$ dihedral of $61.7(3)^{\circ}$ and more planar to the N6 triazole, with an O2-C14-C15-N6 dihedral of 8.4(2) ${ }^{\circ}$.

Crystal Data for $\mathrm{C}_{20} \mathrm{H}_{30} \mathrm{~N}_{8} \mathrm{O}_{2}(M=414.52 \mathrm{~g} / \mathrm{mol})$ : triclinic, space group $P \overline{1}$ (no. 2), $a=4.5792(4) \AA, b=9.5207(8) \AA, c=24.601(2) \AA, \alpha=86.182(4)^{\circ}, \beta=86.199(4)^{\circ}, \gamma=$ $81.258(4)^{\circ}, V=1056.02(16) \AA^{3}, Z=2, T=100 K, \quad \mu(\mathrm{CuK} \alpha)=0.722 \mathrm{~mm}^{-1}, \rho_{\text {calc }}=$ $1.304 \mathrm{~g} / \mathrm{cm}^{3}, 15004$ reflections measured $\left(7.214^{\circ} \leq 2 \Theta \leq 130.154^{\circ}\right), 3565$ unique $\left(R_{\mathrm{int}}=0.0559\right.$,
$\left.R_{\text {sigma }}=0.0481\right)$ which were used in all calculations. The final $R_{1}$ was $0.0961(I \geq 2 \sigma(I))$ and $w R_{2}$ was 0.2957 (all data).

Figure S5 The (a) intermolecular pyrazine...pyrazine hydrogen bonding interactions [1] (shown using


(a)


a blue line) of parallel molecules, between alternating orientations of adjacent pyrazine and (b) the triazole $\cdots$ triazole hydrogen bonding interactions between layers of molecules [2] and [3] (shown using blue lines). Ellipsoids are drawn at the $50 \%$ probability level.

The ligands are held together by intermolecular hydrogen bonding interactions between the two pyrazine centres of the alternate ligand arrangements, with the C 1 pyrazine carbon of one ligand donating a hydrogen bond to the N5 pyrazine nitrogen of the other ligand, with an $\mathrm{C} \cdots \mathrm{N}$ of 3.391 (4) $\AA$ and a C-H $\cdots \mathrm{N}$ angle of $163.01(16)^{\circ}$, (Fig. S5). Additional intermolecular hydrogen bonding interactions exist between the C 6 triazole carbon donating to the O 2 ether oxygen and N 6 triazole nitrogen of the alternatingly bent arms of the neighbouring ligands, which generate a three-dimensional intermolecular network, (Table 2).

Table: The bond lengths ( $\AA$ ) and angles $\left({ }^{\circ}\right)$ of the intermolecular forces between $\mathbf{L} 2$ ligands in Figure S5

|  | $\mathrm{D}-\mathrm{H} \cdots \mathrm{A}$ | $\mathrm{D}-\mathrm{H} / \AA$ | $\mathrm{H} \cdots \mathrm{A} / \AA$ | $\mathrm{D} \cdots \mathrm{A} / \AA$ | $\mathrm{D}-\mathrm{H} \cdots \mathrm{A} /{ }^{\circ}$ |
| :---: | :---: | :---: | :---: | :---: | :---: |
| $[\mathbf{1}]$ | $\mathrm{C} 1-\mathrm{H} 1 \cdots \mathrm{~N} 5$ | $0.950(3)$ | $2.471(2)$ | $3.391(4)$ | $163.01(16)$ |
| $[\mathbf{2}]$ | $\mathrm{C} 6-\mathrm{H} 6 \cdots \mathrm{O} 2$ | $0.950(3)$ | 2.4922 | $3.351(3)$ | $150.43(15)$ |
| $[3]$ | $\mathrm{C} 6-\mathrm{H} 6 \cdots \mathrm{~N} 6$ | $0.950(3)$ | $2.619(2)$ | $3.369(4)$ | $136.10(17)$ |

## S1.4 SCXRD of organic compounds

| Identification code | 2 | L2 |
| :---: | :---: | :---: |
| Empirical formula | $\mathrm{C}_{10} \mathrm{H}_{12} \mathrm{~N}_{2} \mathrm{O}_{4}$ | $\mathrm{C}_{20} \mathrm{H}_{30} \mathrm{~N}_{8} \mathrm{O}_{2}$ |
| Deposition No. | 2301236 | 2301237 |
| Formula weight | 224.22 | 414.52 |
| Temperature / K | 100.00 | 100.00 |
| Crystal system | monoclinic | triclinic |
| Space group | P2 $1_{1} / \mathrm{c}$ | $P \overline{1}$ |
| $a / \AA$ | 11.3960(17) | 4.5792(4) |
| b/A | 5.4689(8) | 9.5207(8) |
| $c / \AA$ | 8.3487(13) | 24.601(2) |
| $\alpha 1^{\circ}$ | 90 | 86.182(4) |
| $\beta 1^{\circ}$ | 90.197(9) | 86.199(4) |
| $\gamma 1^{\circ}$ | 90 | 81.258(4) |
| Volume / $\AA^{3}$ | 520.32(14) | 1056.02(16) |
| Z | 2 | 2 |
| $\rho_{\text {calc }} / \mathrm{g} \mathrm{cm}^{-3}$ | 1.431 | 1.304 |
| $\mu / \mathrm{mm}^{-1}$ | 0.949 | 0.722 |
| F(000) | 236.0 | 444.0 |
| Crystal size / mm | $0.1 \times 0.04 \times 0.02$ | $0.27 \times 0.07 \times 0.02$ |
| Radiation | $\operatorname{CuK} \alpha(\lambda=1.54178)$ | $\operatorname{CuK} \alpha(\lambda=1.54178)$ |
| $2 \Theta$ range for data collection / ${ }^{\circ}$ | 7.758 to 136.37 | 7.214 to 130.154 |
| Index ranges | $\begin{aligned} & -13 \leq h \leq 13,-6 \leq k \leq 6, \\ & -10 \leq l \leq 10 \end{aligned}$ | $\begin{aligned} & -5 \leq h \leq 5,-10 \leq k \leq 11, \\ & -28 \leq l \leq 28 \end{aligned}$ |
| Reflections collected | 5326 | 15004 |
| Independent reflections | $\begin{aligned} & 927\left[R_{\text {int }}=0.0966,\right. \\ & \left.R_{\text {sigma }}=0.0662\right] \end{aligned}$ | $\begin{aligned} & 3565\left[\mathrm{R}_{\text {int }}=0.0559,\right. \\ & \left.\mathrm{R}_{\text {sigma }}=0.0481\right] \end{aligned}$ |
| Data/restraints/parameters | 927/0/76 | 3565/0/273 |
| Goodness-of-fit on $\mathrm{F}^{\mathbf{2}}$ | 1.166 | 1.250 |
| Final $R$ indexes $[I \geq 2 \sigma(I)]$ | $\mathrm{R}_{1}=0.0780, w \mathrm{R}_{2}=0.2125$ | $\mathrm{R}_{1}=0.0961, w \mathrm{R}_{2}=0.2734$ |
| Final R indexes [all data] | $\mathrm{R}_{1}=0.0807, w \mathrm{R}_{2}=0.2152$ | $\mathrm{R}_{1}=0.1093, w \mathrm{R}_{2}=0.2957$ |
| Largest diff. peak/hole / e $\AA^{-3}$ | 0.80/-0.42 | 1.24/-0.39 |

## S2 Characterization of Products

## S2.1 UV-Vis Specroscopy



UV-vis spectroscopy titration experiments: (Top Left) stepwise addition of $6.1 \mu \mathrm{~L}$ of $5 \times 10^{-3} \mathrm{~mol} \mathrm{~L}^{-1}$ of solution of $\mathrm{Zn}\left(\mathrm{BF}_{4}\right)_{2}$ to a $9.5 \times 10^{-5} \mathrm{~mol} \mathrm{~L}^{-1}$ of $\mathbf{L} \mathbf{2}$ in $\mathrm{CH}_{3} \mathrm{CN}$. (Top Right) stepwise addition of 6.1 $\mu \mathrm{L}$ of $5 \times 10^{-3} \mathrm{~mol} \mathrm{~L}^{-1}$ of solution of $\mathrm{Zn}\left(\mathrm{ClO}_{4}\right)_{2}$ to a $9.5 \times 10^{-5} \mathrm{~mol} \mathrm{~L}^{-1}$ of $\mathbf{L 2}$ in $\mathrm{CH}_{3} \mathrm{CN}$. (Bottom Left) stepwise addition of $3.2 \mu \mathrm{~L}$ of $5 \times 10^{-3} \mathrm{~mol} \mathrm{~L}^{-1}$ of solution of $\mathrm{Zn}\left(\mathrm{ClO}_{4}\right)_{2}$ to a $9.42 \times 10^{-5} \mathrm{~mol} \mathrm{~L}^{-1}$ of $\mathbf{L 4}$ in $\mathrm{CH}_{3} \mathrm{CN}$. (Bottom Right) stepwise addition of $3.2 \mu \mathrm{~L}$ of $5 \times 10^{-3} \mathrm{~mol} \mathrm{~L}^{-1}$ of solution of $\mathrm{Zn}\left(\mathrm{BF}_{4}\right)_{2}$ to a $9.42 \times 10^{-5} \mathrm{~mol} \mathrm{~L}^{-1}$ of $\mathbf{L 4}$ in $\mathrm{CH}_{3} \mathrm{CN}$.

Where the red represents 0 equiv. $\mathrm{Zn}^{2+}$ blue is $0.5 \mathrm{Zn}^{2+}$ equiv. and green $1 \mathrm{Zn}^{2+}$ equiv. added. The inset graphs show the changes in the absorption with the increase of the amount of transition metal ions. The dashed yellow data in graph c represents $1.12 \times 10^{-7} \mathrm{~mol} \mathrm{~L}^{-1}$ of complex $\mathbf{4 a}$ in MeCN , scaled to the peak of the one $\mathrm{Zn}^{2+}$ equiv. indicating the formation of the polymer.

## S2.2 L1 and L2 complexes

(a)

(b)

(c)
(d)


(e)

(f)


Figure S 6 A perspective view of a section of the x-ray structures of (a) the $\mathbf{L} \mathbf{1}$ complex $\mathbf{1 A}$ and (b) the $\mathbf{L} 2$ complex $2 \mathbf{A}$ (which is isostructural with $2 \mathbf{B}$ and $\mathbf{2 C}$ ) with the asymmetric unit labelled. Counterions have been removed for clarity. A summary view of the CP complexes illustrating the variation in the alkyl end-group arrangement, and the N1-M-N2-O1 torsion in (c) $\mathbf{1 A}$; (d) $\mathbf{2 C}$; (e) $\mathbf{2 A}$; and (f) 2B. Ellipsoids are drawn at the $50 \%$ probability level.

With regards to the complexes assembled from the alkyl-end-group ligands $\mathbf{L} \mathbf{1}$ and $\mathbf{L} \mathbf{2}$, all four complexes were solved and refined in centrosymmetric monoclinic space groups: $C 2 / c$ (for $\mathbf{1 A}$, $\mathbf{2 A}$ and 2C) and $P 2_{1} / n$ (for $\mathbf{2 B}$ ), where $\mathbf{1 A}, \mathbf{2 A}$ and $\mathbf{2 C}$ had an asymmetric unit of one half of an $\mathbf{L} 2$ ligand coordinated to a half-occupancy of an $\mathbf{M}^{2+}$ ion, with an associated counterion, while 2B had an asymmetric unit of one $\mathbf{L} 2$ ligand coordinated to a single $\mathrm{Fe}^{2+}$ centre, with two associated perchlorate ions. Additionally, in complex 1A the end two carbon atoms of the propene end group of the $\mathbf{L} \mathbf{1}$ ligand are spatially disordered in a $1: 1$ ratio, and in complex $\mathbf{2 c}$ the middle two carbon atoms of the $\mathbf{L} \mathbf{2}$ butyl end group are disordered in a 1:3 ratio.


1A (100)


1A (a axis)



10


2A (001)


2A (c axis)


Figure S 7 Left hand side: the (100) view; a view down the a-axis; and a view of the $\mathbf{1 A}$ complex polymer. Right hand side: the (001) view; a view down the c-axis; and a view of the $\mathbf{2 A}$ complex polymer
an on

54.



2B(100)


2B (a axis)



2C(001)


2C (c axis)


Figure S 8 Left hand side: the (100) view; a view down the a-axis; and a view of the 2B complex polymer. Right hand side: the (001) view; a view down the c-axis; and a view of the 2 C complex polymer


Figure S 9 The (001) view; a view down the c-axis; and a view of the 2D complex polymer


Figure S 10 A perspective view of a section of the zig-zag polymer strands of complex 1A, analogous to the other ligand $\mathbf{L} \mathbf{1}$ complexes. The perchlorate anions have been removed for clarity. (a) With the distance of 3.66 (7) Å between neighbouring C9 alkene carbons of adjacent CPs [1]. A perspective view of the sphere packing of a 2 D sheets formed by the overlapping of alkyl tails of adjacent coordination polymer chains, as seen down (b) the a -axis and (c and d) the c -axis. The left-most CP is coloured by element, while the middle chain (orange) and right-most chain (green) are coloured to more easily see the overlapping alkyl groups. Ellipsoids are drawn at the $50 \%$ probability level.


Figure S11 A perspective view of a section of the zig-zag polymer strands of complex $\mathbf{2 A}$, analogous to the other ligand $\mathbf{L} 2$ complexes The perchlorate anions have been removed for clarity. A perspective view down the a-axis (a) in an ellipsoidal view, and (b) a sphere packing view, of a section of the zigzag polymer strands of complex, where the butyl end groups are held closely together with distances of [1] C7-C9 ${ }^{1} 3.735$ (7); [2] C8-C9 ${ }^{1} 4.037$ (8); and C8-C9 ${ }^{2} 4.171$ (10) Å. A view down the c-axis (c) in an ellipsoidal view, and (d) a sphere packing view, of a 2D sheets formed by the overlapping of alkyl tails of adjacent coordination polymer chains.

## S2.3 L3 Complexes



Figure S 12 An ellipsoidal view of the length of a 1D polymer chain. The intermolecular $\mathrm{CH}-\pi$ interactions between the calculated C7-C13phenyl centroid (shown as a red sphere) and the C4 carbon of and adjacent chain, resulting in the overlap of planar ligands of adjacent polymer chains of the 3A complex.


Figure S 13 A perspective view down the a-axis of polymer strands of the 3A complex in a sphere packing view. Perchlorate anions have been removed for clarity.

## S2.4 L4 Complexes



Figure S 14 A perspective view of two polymer chains of 4 A 'zipped' together by the $\pi-\pi$ interactions of the C21-C26 centroid of the perpendicular ligands (coloured pink) with the off-set ligands (coloured green) (b) shown in 50\% probability level ellipsoids


Figure S 15 A sphere packing view of the interlocked polymer chains of 4A in a 2D sheet separate polymer chains are coloured for clarity.

## S2.5 Powder XRD spectra

Powder XRD was investigated as a technique for determining sample purity for bulk quantities. Samples tested; $\mathbf{1 A}, \mathbf{2 A}$ and $\mathbf{4 B}$, resulted in patterns that indicate structures corresponding to the crystalline polymer materials exhibited by the SCXRD data.


Figure S 16 The comparison between the calculated and experimental PXRD spectra for $\mathbf{1 A}$.


Figure S 17 The comparison between the calculated and experimental PXRD spectra for $\mathbf{2 A}$.


Figure S 18 The comparison between the calculated and experimental PXRD spectra for 4B.

## S3 NMR Spectra





Figure S19. ${ }^{1} \mathrm{H}$ NMR spectrum of azido butane in $\mathrm{CDCl}_{3}$.


Figure $\mathbf{S 2 0}{ }^{1} \mathrm{H}$ NMR spectrum of phenyl azide in $\mathrm{CDCl}_{3}$.





Figure S21 ${ }^{1} \mathrm{H}$ NMR spectrum of benzyl azide in $\mathrm{CDCl}_{3}$.




Figure S22 ${ }^{1} \mathrm{H}$ NMR spectrum of 2,5-dimethylpyrazine-1,4-N-oxide (1) in DMSO-d ${ }_{6}$.




Figure $\mathbf{S 2 3}{ }^{1} \mathrm{H}$ NMR spectrum of 2,5-bis(acetoxymethyl)pyrazine (2) in $\mathrm{CDCl}_{3}$.


Figure $\mathbf{S 2 4}{ }^{1} \mathrm{H}$ NMR spectrum of 2,5-bis(hydroxymethyl)pyrazine (3) in DMSO-d ${ }_{6}$.


Figure S25 ${ }^{1} \mathrm{H}$ NMR spectrum of 2,5-bis((prop-2-yn-1-yloxy)methyl)pyrazine (4) in DMSO-d $\mathrm{d}_{6}$.


Figure S26 ${ }^{13}$ C NMR spectrum of 2,5-bis((prop-2-yn-1-yloxy)methyl)pyrazine (4) in DMSO-d ${ }_{6}$.


Figure $\mathbf{S 2 7}{ }^{1} \mathrm{H}$ NMR spectrum of $\mathbf{L} \mathbf{1}$ in DMSO-d ${ }_{6}$.




Figure S28 ${ }^{13} \mathrm{C}$ NMR spectrum of $\mathbf{L} 1$ in DMSO-d ${ }_{6}$.


Figure S29 ${ }^{1} \mathrm{H}$ NMR spectrum of $\mathbf{L} \mathbf{2}$ in DMSO-d ${ }_{6}$.

| $\stackrel{\sim}{\sim}$ |  |
| :---: | :---: |
| ヘัٌ | ¢ัֹ |
|  | // |




Figure $\mathbf{S 3 0}{ }^{13} \mathrm{C}$ NMR spectrum of $\mathbf{L} \mathbf{2}$ in $\mathrm{DMSO}-\mathrm{d}_{6}$.


Figure $\mathbf{S 3 1}{ }^{1} \mathrm{H}$ NMR spectrum of $\mathbf{L 3}$ in $\mathrm{DMSO}-\mathrm{d}_{6}$.




Figure $\mathbf{S 3 2}{ }^{13} \mathbf{C}$ NMR spectrum of $\mathbf{L} \mathbf{3}$ in DMSO-d ${ }_{6}$.


Figure S $33{ }^{1} \mathrm{H}$ NMR spectrum of $\mathbf{L} \mathbf{4}$ in DMSO.


Figure $\mathbf{S} 34{ }^{13} \mathrm{C}$ NMR spectrum of $\mathbf{L 4}$ in DMSO.

## S4 Infrared Spectra

## S4.1 ATR-IR : organic precursors and ligands



Figure S $\mathbf{3 5}$ ATR-IR of alkyne compound $\mathbf{4}$


Figure S $\mathbf{3 6}$ ATR-IR of L1


Figure S $\mathbf{3 7}$ ATR-IR of L2


Figure S 38 ATR-IR of L3


Figure S 39 ATR-IR of L4

## S4.2 ATR-IR : coordination polymer complexes



Figure S 40 Complex 1A: $\left\{[\mathrm{Cu}(\mathbf{L} 1)]\left(\mathrm{ClO}_{4}\right)_{2}\right\}_{\mathrm{n}}$


Figure S 41 Complex 2A: $\left\{[\mathrm{Zn}(\mathbf{L} 2)]\left(\mathrm{BF}_{4}\right)_{2}\right\}_{\mathrm{n}}$


Figure S 42 Complex 2B: $\left\{[\mathrm{Fe}(\mathbf{L 2})]\left(\mathrm{ClO}_{4}\right)_{2}\right\}_{\mathrm{n}}$


Figure S 43 Complex 2C: $\left\{[\mathrm{Cu}(\mathbf{L 2})]\left(\mathrm{ClO}_{4}\right)_{2}\right\}_{\text {n }}$


Figure S 44 Complex 3A: $\left\{[\mathrm{Mn}(\mathbf{L 3})]\left(\mathrm{ClO}_{4}\right)_{2}\right\}_{\mathrm{n}}$


Figure S 45 Complex 3B: $\left\{[\mathrm{Zn}(\mathbf{L 3})]\left(\mathrm{ClO}_{4}\right)_{2}\right\}$


Figure S 46 3C: $\left\{[\mathrm{Zn}(\mathbf{L 3})](\mathrm{OTf})_{2}\right\}_{\infty}$


Figure S 47 Complex 4A: $\left\{[\mathrm{Zn}(\mathrm{L} 4)]\left(\mathrm{ClO}_{4}\right)_{2}\right\}_{\mathrm{n}}$


Figure S 48 Complex 4B: $\left\{[\mathrm{Co}(\mathbf{L} 4)]\left(\mathrm{ClO}_{4}\right)_{2}\right\}_{\mathrm{n}}$


Figure S 49 Complex 4C: $\left\{[\mathrm{Cu}(\mathbf{L 4})]\left(\mathrm{ClO}_{4}\right)_{2}\right\}_{\mathrm{n}}$

## References

B. Yang, H. Zhang, H. Peng, Y. Xu, B. Wu, W. Weng and L. Li, Polym. Chem., 2014, 5, 1945-1953.
2.
K. Darrah, T. Wang, I. Cook, M. Cacace, A. Deiters and T. S. Leyh, J. Biol. Chem., 2019, 294, 2293-2301.
J.-W. Zhao, J.-W. Guo, M.-J. Huang, Y.-Z. You, Z.-H. Wu, H.-M. Liu and L.-H. Huang, Steroids, 2019, 150, 108431.
M. Kitamura, M. Yano, N. Tashiro, S. Miyagawa, M. Sando and T. Okauchi, Eur. J. Inorg. Chem., 2011, 2011, 458-462.
Q. Yan, X. Shen, G. Zi and G. Hou, Eur. J. Chem., 2020, 26, 5961-5964.
J. Pietruszka and G. Solduga, Eur. J. Inorg. Chem., 2009, 2009, 5998-6008.
S. K. Das and J. Frey, Tetrahedron Lett., 2012, 53, 3869-3872.
D. D. Perrin, W. L. Armarego and D. R. Perrin, Purification of laboratory chemicals, 1988.
I. Delso, J. Valero-Gonzalez, F. Gomollón-Bel, J. Castro-López, W. Fang, I. Navratilova, D. M. F. van Aalten, T. Tejero, P. Merino and
R. Hurtado-Guerrero, ChemMedChem, 2018, 13, 128-132.

